CEGEDIM SA (CGM.PA) Stock Fundamental Analysis
EPA:CGM - Euronext Paris - Matif - FR0000053506 - Common Stock - Currency: EUR
We assign a fundamental rating of 3 out of 10 to CGM. CGM was compared to 11 industry peers in the Health Care Technology industry. CGM may be in some trouble as it scores bad on both profitability and health. CGM is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CGM has reported negative net income.
In the past year CGM had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CGM reported negative net income in multiple years.
Each year in the past 5 years CGM had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -1.49%, CGM perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
Looking at the Return On Equity, with a value of -5.56%, CGM is in line with its industry, outperforming 45.45% of the companies in the same industry.
CGM has a Return On Invested Capital (4.46%) which is comparable to the rest of the industry.
CGM had an Average Return On Invested Capital over the past 3 years of 2.87%. This is below the industry average of 7.26%.
The 3 year average ROIC (2.87%) for CGM is below the current ROIC(4.46%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.49% | ||
| ROE | -5.56% | ||
| ROIC | 4.46% |
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
1.3 Margins
With a Operating Margin value of 5.75%, CGM perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
In the last couple of years the Operating Margin of CGM has declined.
CGM has a Gross Margin of 20.07%. This is amonst the worse of the industry: CGM underperforms 81.82% of its industry peers.
CGM's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.75% | ||
| PM (TTM) | N/A | ||
| GM | 20.07% |
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CGM is still creating some value.
The number of shares outstanding for CGM has been increased compared to 1 year ago.
Compared to 5 years ago, CGM has less shares outstanding
Compared to 1 year ago, CGM has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.28, we must say that CGM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.28, CGM is in line with its industry, outperforming 54.55% of the companies in the same industry.
CGM has a debt to FCF ratio of 27.31. This is a negative value and a sign of low solvency as CGM would need 27.31 years to pay back of all of its debts.
CGM has a Debt to FCF ratio (27.31) which is in line with its industry peers.
A Debt/Equity ratio of 1.14 is on the high side and indicates that CGM has dependencies on debt financing.
CGM's Debt to Equity ratio of 1.14 is on the low side compared to the rest of the industry. CGM is outperformed by 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 27.31 | ||
| Altman-Z | 1.28 |
ROIC/WACC1.08
WACC4.14%
2.3 Liquidity
A Current Ratio of 0.99 indicates that CGM may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.99, CGM is doing worse than 63.64% of the companies in the same industry.
CGM has a Quick Ratio of 0.99. This is a bad value and indicates that CGM is not financially healthy enough and could expect problems in meeting its short term obligations.
CGM's Quick ratio of 0.97 is on the low side compared to the rest of the industry. CGM is outperformed by 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
CGM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -97.97%.
The Revenue has been growing slightly by 6.25% in the past year.
The Revenue has been growing slightly by 5.38% on average over the past years.
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
3.2 Future
Based on estimates for the next years, CGM will show a very strong growth in Earnings Per Share. The EPS will grow by 24.45% on average per year.
Based on estimates for the next years, CGM will show a small growth in Revenue. The Revenue will grow by 3.51% on average per year.
EPS Next Y30.09%
EPS Next 2Y24.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.92%
Revenue Next 2Y3.51%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 7.64, the valuation of CGM can be described as very cheap.
Based on the Price/Forward Earnings ratio, CGM is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, CGM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.64 |
4.2 Price Multiples
CGM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CGM is cheaper than 100.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CGM indicates a rather cheap valuation: CGM is cheaper than 90.91% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.41 | ||
| EV/EBITDA | 3.34 |
4.3 Compensation for Growth
CGM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CGM's earnings are expected to grow with 24.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.45%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CGM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:CGM (5/29/2025, 5:12:18 PM)
11.35
-0.1 (-0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners17.48%
Inst Owner ChangeN/A
Ins Owners54.22%
Ins Owner ChangeN/A
Market Cap160.03M
Analysts48.89
Price Target13.94 (22.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.53%
PT rev (3m)-10.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-6.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.64 | ||
| P/S | 0.24 | ||
| P/FCF | 13.41 | ||
| P/OCF | 1.57 | ||
| P/B | 0.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.34 |
EPS(TTM)-1.07
EYN/A
EPS(NY)1.48
Fwd EY13.08%
FCF(TTM)0.85
FCFY7.46%
OCF(TTM)7.22
OCFY63.64%
SpS46.42
BVpS18.75
TBVpS-11.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.49% | ||
| ROE | -5.56% | ||
| ROCE | 6.06% | ||
| ROIC | 4.46% | ||
| ROICexc | 4.84% | ||
| ROICexgc | 19.22% | ||
| OM | 5.75% | ||
| PM (TTM) | N/A | ||
| GM | 20.07% | ||
| FCFM | 1.82% |
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
ROICexc(3y)3.13%
ROICexc(5y)4.15%
ROICexgc(3y)11.62%
ROICexgc(5y)15.26%
ROCE(3y)3.91%
ROCE(5y)5.29%
ROICexcg growth 3Y0.21%
ROICexcg growth 5Y-3.19%
ROICexc growth 3Y-3.24%
ROICexc growth 5Y-2.52%
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
F-Score3
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 27.31 | ||
| Debt/EBITDA | 2.3 | ||
| Cap/Depr | 96.22% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 4.24 | ||
| Cash Conversion | 77.7% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 1.28 |
F-Score3
WACC4.14%
ROIC/WACC1.08
Cap/Depr(3y)92.57%
Cap/Depr(5y)94.88%
Cap/Sales(3y)13.24%
Cap/Sales(5y)13.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
EPS Next Y30.09%
EPS Next 2Y24.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
Revenue Next Year2.92%
Revenue Next 2Y3.51%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y79.81%
EBIT growth 3Y0.5%
EBIT growth 5Y1.66%
EBIT Next Year278.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-46.81%
FCF growth 3Y-27.43%
FCF growth 5YN/A
OCF growth 1Y4.01%
OCF growth 3Y2%
OCF growth 5Y28.33%